CN101848901B - 用于治疗高血压的噻唑烷二酮类似物 - Google Patents

用于治疗高血压的噻唑烷二酮类似物 Download PDF

Info

Publication number
CN101848901B
CN101848901B CN2008801147383A CN200880114738A CN101848901B CN 101848901 B CN101848901 B CN 101848901B CN 2008801147383 A CN2008801147383 A CN 2008801147383A CN 200880114738 A CN200880114738 A CN 200880114738A CN 101848901 B CN101848901 B CN 101848901B
Authority
CN
China
Prior art keywords
thiazolidine
benzyl
diketone
group
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801147383A
Other languages
English (en)
Chinese (zh)
Other versions
CN101848901A (zh
Inventor
杰勒德·R·科尔卡
罗伯特·C·加德伍德
蒂姆·帕克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siri Maher J Therapy Ltd By Share Ltd
Original Assignee
Metabolic Solutions Development Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Development Co LLC filed Critical Metabolic Solutions Development Co LLC
Publication of CN101848901A publication Critical patent/CN101848901A/zh
Application granted granted Critical
Publication of CN101848901B publication Critical patent/CN101848901B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801147383A 2007-09-14 2008-09-15 用于治疗高血压的噻唑烷二酮类似物 Active CN101848901B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97263907P 2007-09-14 2007-09-14
US60/972,639 2007-09-14
PCT/US2008/010723 WO2009038681A1 (en) 2007-09-14 2008-09-15 Thiazolidinedione analogues for the treatment of hypertension

Publications (2)

Publication Number Publication Date
CN101848901A CN101848901A (zh) 2010-09-29
CN101848901B true CN101848901B (zh) 2012-11-21

Family

ID=40239575

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801147383A Active CN101848901B (zh) 2007-09-14 2008-09-15 用于治疗高血压的噻唑烷二酮类似物

Country Status (15)

Country Link
US (1) US8067450B2 (OSRAM)
EP (1) EP2203433B1 (OSRAM)
JP (1) JP5371988B2 (OSRAM)
KR (1) KR101537830B1 (OSRAM)
CN (1) CN101848901B (OSRAM)
AU (1) AU2008301905B2 (OSRAM)
BR (1) BRPI0817096B8 (OSRAM)
CA (1) CA2699289C (OSRAM)
ES (1) ES2398313T3 (OSRAM)
IL (1) IL204440A (OSRAM)
MX (1) MX2010002820A (OSRAM)
NZ (2) NZ597381A (OSRAM)
PL (1) PL2203433T3 (OSRAM)
RU (1) RU2486179C2 (OSRAM)
WO (1) WO2009038681A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2388555T3 (es) 2006-03-16 2012-10-16 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
CA2646207C (en) 2006-03-16 2016-01-19 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
NZ597381A (en) 2007-09-14 2013-03-28 Metabolic Solutions Dev Co Llc Thiazolidinedione analogues for the treatment of diabetes and inflammatory diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
WO2010105048A1 (en) * 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
KR20120092712A (ko) * 2009-12-15 2012-08-21 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 진성 당뇨병 및 다른 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
CA2783556C (en) * 2009-12-15 2017-12-12 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
HUE038042T2 (hu) * 2009-12-15 2018-09-28 Cirius Therapeutics Inc PPAR helyettesítõ tiazolidindion sók metabolikus betegségek kezelésére
AU2014202074B2 (en) * 2009-12-15 2016-01-07 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
MX2012006734A (es) * 2009-12-15 2012-07-03 Metabolic Solutions Dev Co Llc Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2560956B1 (en) * 2010-04-19 2016-10-26 Octeta Therapeutics, LLC Novel synthesis for thiazolidinedione compounds
AU2011242844A1 (en) * 2010-04-21 2012-11-01 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
HUE031424T2 (en) * 2010-08-10 2017-07-28 Octeta Therapeutics Llc New synthesis of thiazolidinedione compounds
PL2603507T3 (pl) * 2010-08-10 2016-12-30 Synteza związków tiazolidynodionu
WO2012109495A1 (en) * 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012149083A1 (en) * 2011-04-28 2012-11-01 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones for the treatment of kidney related diseases
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
JP6800013B2 (ja) * 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ 重水素化２，４−チアゾリジンジオン及び治療方法
JP6498195B2 (ja) 2013-07-22 2019-04-10 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 代謝疾患を処置するためのｐｐａｒ節約化合物
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
WO2019154958A1 (en) 2018-02-08 2019-08-15 Enyo Pharma Use of modulators of neet proteins for the treatment of infection
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008203A1 (en) * 1978-08-04 1980-02-20 Takeda Chemical Industries, Ltd. Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same
EP0549365A1 (en) * 1991-12-26 1993-06-30 Sankyo Company Limited Thiazolidine compounds, their preparation and their therapeutic uses

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
WO1986002073A1 (fr) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5356913A (en) 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
WO1992018501A1 (en) 1991-04-11 1992-10-29 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
CZ289317B6 (cs) * 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5798375A (en) 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
WO2000066102A2 (en) 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
DK1192137T3 (da) 1999-06-30 2013-11-11 Amgen Inc Forbindelser til modulering af PPAR-gamma aktivitet
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
AU2002311057A1 (en) 2001-04-26 2002-11-11 Leciva, A.S. Method for obtaining pioglitazone as an antidiabetic agent
AU2002337749A1 (en) 2001-09-28 2003-04-07 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
AU2003272072A1 (en) 2002-07-16 2004-02-02 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
EP1607103A1 (en) * 2003-03-20 2005-12-21 Eisai Co., Ltd. Concomitant drug as therapeutic agent for inflammatory bowel disease
US7230016B2 (en) 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
JP2005015477A (ja) * 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
US20070078170A1 (en) 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
AU2005288080B2 (en) 2004-09-28 2011-10-13 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound
MX2008011870A (es) 2006-03-16 2009-02-10 Metabolic Solutions Dev Compan Terapias de combinacion de analogos de tiazolidindiona y agonistas glucocorticoides.
ES2388555T3 (es) * 2006-03-16 2012-10-16 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
CA2646207C (en) 2006-03-16 2016-01-19 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
NZ597381A (en) 2007-09-14 2013-03-28 Metabolic Solutions Dev Co Llc Thiazolidinedione analogues for the treatment of diabetes and inflammatory diseases
WO2010105048A1 (en) 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008203A1 (en) * 1978-08-04 1980-02-20 Takeda Chemical Industries, Ltd. Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same
EP0549365A1 (en) * 1991-12-26 1993-06-30 Sankyo Company Limited Thiazolidine compounds, their preparation and their therapeutic uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Pietro Gerber et al..Effects of pioglitazone on metabolic control and blood pressure: A randomised study in patients with type 2 diabetes mellius.《Current Medical Research and Opinion》.2003,第19卷(第6期),532-539. *
Steven P. Tanis, et al..Synthesis and Biological Activity of Metabolites of the Antidiabetic, Antihyperglycemic Agent Pioglitazone.《J. Med. Chem.》.1996,第39卷(第26期),5053-5063. *
StevenP.Tanis et al..Synthesis and Biological Activity of Metabolites of the Antidiabetic
Takashi Sohda, et al..Studies on Antidiabetic Agents. II. Synthesis of 5-[4-(1-Methylcyclohexylmethoxy)-benzyl] thiazolidine-2, 4-dione (ADD-3878) and Its Derivatives.《Chem. Pharm. Bull.》.1982,第30卷(第10期),3580-3600. *

Also Published As

Publication number Publication date
BRPI0817096B1 (pt) 2020-11-10
US20100222399A1 (en) 2010-09-02
EP2203433B1 (en) 2012-10-31
WO2009038681A1 (en) 2009-03-26
HK1146484A1 (en) 2011-06-10
CN101848901A (zh) 2010-09-29
NZ583889A (en) 2012-01-12
NZ597381A (en) 2013-03-28
ES2398313T3 (es) 2013-03-15
BRPI0817096A2 (pt) 2017-05-02
MX2010002820A (es) 2010-04-01
RU2486179C2 (ru) 2013-06-27
AU2008301905A1 (en) 2009-03-26
RU2010114727A (ru) 2011-10-20
US8067450B2 (en) 2011-11-29
CA2699289C (en) 2016-01-19
KR101537830B1 (ko) 2015-07-17
BRPI0817096B8 (pt) 2021-05-25
IL204440A (en) 2013-05-30
PL2203433T3 (pl) 2013-04-30
JP2010539171A (ja) 2010-12-16
KR20100075915A (ko) 2010-07-05
CA2699289A1 (en) 2009-03-26
AU2008301905B2 (en) 2013-06-27
EP2203433A1 (en) 2010-07-07
BRPI0817096A8 (pt) 2017-10-10
JP5371988B2 (ja) 2013-12-18

Similar Documents

Publication Publication Date Title
CA2699289C (en) Thiazolidinedione analogues for the treatment of hypertension
CN101454005B (zh) 用于治疗代谢性炎症介导的疾病的噻唑烷二酮类似物
EP2512470B1 (en) Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
CN101454006B (zh) 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物
JP2010539171A5 (OSRAM)
EP2513070B1 (en) Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
WO2010105048A9 (en) Thiazolidinedione analogues
WO2011084459A1 (en) Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
CN102753170A (zh) 治疗糖尿病及其它代谢性疾病的ppar节制的噻唑烷二酮和组合
KR20130064742A (ko) 티아졸리딘디온 유사체
US8304441B2 (en) Thiazolidinedione analogues for the treatment of metabolic diseases
HK1146484B (en) Thiazolidinedione analogues for the treatment of hypertension
HK1178066A (en) Thiazolidinedione analogues
AU2013200104B2 (en) Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
WO2012178142A1 (en) Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases
HK1174330B (en) Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
HK1174278A (en) Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1146484

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: METABOLIC SOLUTIONS DEV COMPAN

Free format text: FORMER NAME: METABOLIC SOLUTIONS DEVELOPMENT COMPANY

Owner name: METABOLIC SOLUTIONS DEVELOPMENT COMPANY

Free format text: FORMER NAME: METABOLIC SOLUTIONS DEV COMPAN

CP01 Change in the name or title of a patent holder

Address after: michigan

Patentee after: METABOLIC SOLUTIONS DEVELOPMENT CO.

Address before: michigan

Patentee before: Mayta Bolick solutions development

Address after: michigan

Patentee after: Mayta Bolick solutions development

Address before: michigan

Patentee before: METABOLIC SOLUTIONS DEVELOPMENT CO.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1146484

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20161026

Address after: michigan

Patentee after: Octeta Therapy LLC

Address before: michigan

Patentee before: METABOLIC SOLUTIONS DEVELOPMENT CO.

CP01 Change in the name or title of a patent holder

Address after: michigan

Patentee after: Siri Maher J therapy Limited by Share Ltd.

Address before: michigan

Patentee before: Octeta Therapy LLC

CP01 Change in the name or title of a patent holder